ArticleCancer2010
Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.
Article in Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 91 citations in OpenAlex.
- Assessing metabolic alterations and cancer biomarkers in athymic nude mice implanted with NSCLC spheroids.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- The Use of Biologics for Targeting GPCRs in Metastatic Cancers.Biotech (Basel (Switzerland)) · 2025Review
- Role of Cancer Side Population Stem Cells in Ovarian Cancer Angiogenesis.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Review
- Combination of BFHY with Cisplatin Relieved Chemotherapy Toxicity and Altered Gut Microbiota in Mice.International journal of genomics · 2023Article
- The Emerging Role of Adhesion GPCRs in Cancer.ACS pharmacology & translational science · 2020Review
- Interfering Human Papillomavirus E6/E7 Oncogenes in Cervical Cancer Cells Inhibits the Angiogenesis of Vascular Endothelial Cells via Increasing miR-377 in Cervical Cancer Cell-Derived Microvesicles.OncoTargets and therapy · 2020Article
- Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.Cancer letters · 2018Article
- Role of autotaxin in cancer stem cells.Cancer metastasis reviews · 2018Review
- Design of spherically structured 3D in vitro tumor models -Advances and prospects.Acta biomaterialia · 2018Review
- G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts.International journal of molecular sciences · 2017Review
- Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer.International journal of biological sciences · 2017Article
- Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development.Mediators of inflammation · 2017Review
- Bioprinting Cellularized Constructs Using a Tissue-specific Hydrogel Bioink.Journal of visualized experiments : JoVE · 2016Article
- Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.Journal of lipid research · 2016Review
- Establishment and characterization of intraperitoneal xenograft models by co-injection of human tumor cells and extracellular matrix gel.Oncology letters · 2015Article
- Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.Bioorganic & medicinal chemistry · 2015Article
- Hypoxia and free radicals: role in tumor progression and the use of engineering-based platforms to address these relationships.Free radical biology & medicine · 2015Review
- Autotaxin-LPA receptor axis in the pathogenesis of lung diseases.International journal of clinical and experimental medicine · 2015Review
- Promising pharmacological directions in the world of lysophosphatidic Acid signaling.Biomolecules & therapeutics · 2015Review
- 3D tissue-engineered model of Ewing's sarcoma.Advanced drug delivery reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
background: We developed an engineered three-dimensional (3D) tumor xenograft model of nonsmall cell lung cancer (NSCLC) in nude mice, and we used this model to evaluate a dual-activity inhibitor of lysophosphatidic acid (LPA) biosynthesis and receptor activation.
methods: First, BrP-LPA, a pan-antagonist for 4 LPA receptors and inhibitor of the lyosphospholipase D activity of autotaxin, was examined for inhibition of cell migration and cell invasion by human NSCLC A549 cells. Second, A549 cells were encapsulated in 3D in 3 semisynthetic extracellular matrices (ECMs) based on chemically modified glycosaminoglycans, and injected subcutaneously in nude mice. Tumor volume and vascularity were determined as a function of semisynthetic ECMs composition. Third, engineered NSCLC xenografts were formed from A549 cells in either Extracel-HP or Matrigel, and mice were treated with 4 intraperitoneal injections of 3 mg/kg of BrP-LPA.
results: First, BrP-LPA inhibited cell migration and invasiveness of A549 cells in vitro. Second, tumor growth and microvessel formation for 3D encapsulated A549 cells in vivo in nude mice increased in the following order: buffer only < Extracel < Extracel-HP < Extracel-HP containing growth factorss plus laminin. Third, tumor volumes increased rapidly in both Matrigel and Extracel-HP encapsulated A549 cells, and tumor growth was markedly inhibited by BrP-LPA treatment. Finally, tumor vascularization was dramatically reduced in the A549 tumors treated with BrP-LPA.
conclusions: Engineered A549 lung tumors can be created by 3D encapsulation in an ECM substitute with user controlled composition. The engineered tumors regress and lose vascularity in response to a dual activity inhibitor of the LPA signaling pathway. Cancer 2010. (c) 2010 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.